Merck & Co. Aktie News

Merck is in talks to buy cancer drug developer Revolution Medicines , the Financial Times reported on Thursday, citing people familiar with the matter.

Merck has surged nearly 30% since my prior bullish call, reflecting strong share price momentum. MRK fundamentals are robust, underpinned by stellar financial performance and promising regulatory developments. Valuation remains highly attractive, with improving market sentiment supporting continued upside.

Eli Lilly's GLP-1 weight loss drug is leading investors to award it a massive P/E ratio of 53. That's far higher than the pharmaceutical sector's average P/E ratio of about 30.

Merck could lose up to $630 million in Gardasil revenue this year now that the U.S. no longer recommends three doses of the HPV shot in the childhood vaccine schedule, according to Jefferies analysts.

DUBAI, United Arab Emirates--(BUSINESS WIRE)-- #100MostInfluentialAfricans--Dr. Rasha Kelej, CEO of Merck Foundation, has been recognized as one of the 100 Most Influential Africans by New African Magazine (UK).

BofA Securities is the investment banking and capital markets division of Bank of America, one of the largest financial institutions in the United States.

BRISBANE, Australia and CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive Officer to lead the commercialisation of the Company's proprietary high‑density microarray patch (HD‑MAP) vaccination technology.

Steven Cress answers your questions! Credo Technology maintains A+ momentum rating, outperforming its sector across multiple timeframes despite recent stagnation concerns.